Financial Performance - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 25% year-over-year growth[2]. - Total revenue increased by 18.1% from RMB 625.4 million in 2022 to RMB 738.5 million in 2023, primarily driven by the rapid growth in sales of Obinutuzumab[50]. - Gross profit rose by 26.6% from RMB 482.0 million in 2022 to RMB 610.1 million in 2023, with a gross margin of 82.6%, up from 77.1% in the previous year[51]. - Net loss decreased by 27.8% from RMB 893.7 million in 2022 to RMB 645.6 million in 2023[52]. - Other income and gains rose from RMB 198.2 million in 2022 to RMB 244.2 million in 2023, largely due to an increase in bank interest income[51]. - Total expenses decreased from RMB 1,550.5 million in 2022 to RMB 1,404.3 million in 2023, attributed to improved operational efficiency[51]. - Cash and bank balances as of December 31, 2023, were approximately RMB 8.22 billion, providing flexibility for clinical development and investment in competitive product lines[52]. Market Expansion and Product Development - The company provided guidance for the next fiscal year, projecting revenue growth of 20% to reach between $600 million and $720 million[2]. - The company is expanding its market presence in Europe, targeting a 15% market share by the end of the next fiscal year[2]. - New product launches included two innovative therapies, expected to contribute an additional $100 million in revenue over the next year[2]. - The company aims to establish leadership in the hematological oncology field through a robust pipeline and strategic drug development initiatives[30]. - The company plans to invest $50 million in digital marketing to enhance customer engagement and drive sales growth[2]. Research and Development - Research and development expenses increased to $80 million, accounting for 16% of total revenue, reflecting the company's commitment to innovation[2]. - The company has a strong pipeline with 13 valuable drug candidates, including 2 commercialized products and over 30 ongoing global trials at various clinical stages[29]. - The company is focused on advancing research in B-cell and T-cell pathways for autoimmune diseases, aiming to address unmet clinical needs[60]. - The company is actively developing new technologies such as PROTAC, XDC, and molecular glue to enhance its drug development capabilities[129]. Clinical Trials and Approvals - The company received regulatory approval for its lead drug candidate, which is expected to launch in Q3 of the next fiscal year[2]. - The new drug application for relapsed refractory marginal zone lymphoma (MZL) was approved in April 2023, making it the first and only approved BTK inhibitor for this indication in China[31]. - The company successfully completed patient recruitment for a Phase III registration trial for CLL/SLL first-line treatment in the first half of 2023, with NDA submission expected in the second half of 2024[31]. - The company is conducting a Phase III clinical trial for MCD subtype DLBCL, comparing Obinutuzumab combined with R-CHOP to R-CHOP alone, with patient recruitment ongoing at 45 clinical centers in China[32]. Strategic Acquisitions and Collaborations - The company announced a strategic acquisition of a biotech firm for $200 million, aimed at enhancing its product pipeline[2]. - The company is collaborating with ArriVent Biopharma to evaluate the combination therapy of ICP-189 with furmonertinib for advanced non-small cell lung cancer patients[125]. Financial Position and Investments - The company has a strong cash position with a total cash balance of RMB 8.2 billion at year-end, providing financial stability and flexibility[57]. - The company has completed the second phase of construction at its Guangzhou facility, adding 30,000 square meters to support ongoing drug development and business expansion[130]. - The company has a bank credit line of RMB 400 million, of which RMB 33.8 million has been drawn down, leaving RMB 366.2 million undrawn[174]. Governance and Management - The company has a strong board with members possessing extensive experience in the pharmaceutical and biotechnology industries, including investment management and academic leadership[185]. - The board's composition reflects a commitment to governance and oversight, with members serving on various committees such as audit, compensation, and nomination[185]. - The management team has a strong background in drug discovery and development, with over 30 years of experience in the pharmaceutical industry[189]. Future Outlook - The company aims to become a global leader in biopharmaceuticals by leveraging its robust R&D capabilities and diverse drug portfolio[192]. - The company plans to commercialize multiple innovative drugs in the coming years, enhancing global patient access to its therapies[61].

Financial Performance - The company reported a net loss of 646 million yuan for 2023, with a cash-adjusted loss of 491 million yuan after excluding non-cash items [3]. - The company does not plan to distribute profits for the 2023 fiscal year, pending approval at the shareholders' annual meeting [5]. - The company reported a revenue of RMB 1.2 billion for the fiscal year 2023, representing a year-over-year growth of 25% [13]. - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year 2023, representing a 25% year-over-year growth [18]. - The company's operating revenue for 2023 was ¥738,537,047.65, representing an 18.09% increase compared to ¥625,404,169.95 in 2022 [23]. - The net profit attributable to shareholders for 2023 was -¥631,262,907.71, an improvement from -¥886,593,114.73 in 2022 [23]. - The net cash flow from operating activities decreased to -¥665,489,513.23 in 2023 from -¥490,583,554.63 in 2022 [23]. - Basic and diluted earnings per share for 2023 were -¥0.37, compared to -¥0.60 in 2022 [24]. - The company reported a net loss attributable to shareholders of -¥100,097,399.14 in Q4 2023, following losses of -¥12,406,466.71 in Q1, -¥409,803,081.78 in Q2, and -¥108,955,960.08 in Q3 [26]. Research and Development - Research and development expenses increased by 16.73% year-on-year to 757 million yuan, reflecting ongoing investments in new technology platforms and clinical trials [3]. - The R&D investment for new products and technologies increased by 30%, totaling RMB 300 million in 2023 [13]. - Research and development expenses increased by 40%, totaling $80 million, to support new technology initiatives [18]. - Research and development expenses accounted for 102.53% of operating revenue in 2023, slightly down from 103.73% in 2022 [24]. - The company’s R&D investment was significantly high, reflecting its commitment to innovation despite the financial losses [24]. - The total R&D investment for the year reached ¥757,253,137.36, an increase of 16.73% compared to ¥648,702,607.78 in the previous year [145]. - The company has established four core technology platforms, including compound optimization and drug solubility enhancement, to accelerate drug discovery and development [141]. - The company has developed a highly efficient self-research platform covering early drug discovery to late clinical development, with 13 products in I/II/III clinical trial stages as of March 28, 2024 [151]. Product Pipeline and Market Strategy - The company has established a rich product pipeline in hematological malignancies, autoimmune diseases, and solid tumors, with its core product, Obinutuzumab, already commercialized [3]. - Tafasitamab has been approved in Hong Kong and is recognized as a clinically needed imported drug in the Greater Bay Area and Boao Super Hospital [3]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025 [13]. - The company is expanding its market presence in Europe, targeting a 15% market share by the end of 2024 [18]. - The company launched two new drugs in Q4 2023, contributing to a 10% increase in overall sales [13]. - The company is actively pursuing market expansion and commercialization strategies, including partnerships with quality CMO for production support [32]. - The company aims to establish leadership in the hematological malignancies field, with a focus on covering NHL, MM, and leukemia using ibrutinib as a core therapy [56]. Clinical Trials and Drug Development - The company has 13 products in clinical trials across I/II/III phases, focusing on oncology and autoimmune diseases, with significant unmet clinical needs [31]. - Acalabrutinib has been included in the 2021 CSCO lymphoma diagnosis and treatment guidelines and is recommended for multiple indications, enhancing its market competitiveness [32]. - The company has initiated a Phase III clinical trial for Obinutuzumab in ITP, with the first patient enrolled in October 2023 and expected completion of recruitment by the end of 2024 or early 2025 [43]. - The company is conducting a Phase II clinical trial for Acalabrutinib in relapsed or refractory MCL in the U.S., with NDA submission anticipated in the second half of 2024 [35]. - Tafasitamab (Minjuvi®) is undergoing a bridging Phase II clinical trial for relapsed or refractory DLBCL in mainland China, with NDA submission expected in Q2 2024 and approval anticipated in the first half of 2025 [36]. - ICP-248, a novel oral BCL2 inhibitor, is in a Phase I dose-escalation trial, showing promising safety and efficacy data, with an ORR of 100% in evaluable patients at the 100 mg QD RP2D dose [38]. - The company has initiated a Phase III trial for ibrutinib in treating immune thrombocytopenia (ITP) patients, with promising proof of concept (PoC) data reported [80]. Market and Competitive Landscape - The global market for autoimmune disease treatments is projected to reach $185 billion by 2029, with a CAGR of 3.7%, driven by the increasing incidence of autoimmune diseases and rising treatment costs [42]. - The company faces significant competition in the market, with existing products and those in clinical trials posing risks to the market share of Obinutuzumab, particularly from competitors like Ibrutinib and Zepzelca, which were approved earlier in China [169]. - The global pharmaceutical market size reached $1,298.8 billion in 2020, projected to grow to $1,711.4 billion by 2025, with a CAGR of 5.7% from 2020 to 2025 [117]. - The global anti-tumor drug market grew from $93.7 billion in 2016 to $150.3 billion in 2020, with a CAGR of 12.5%, and is projected to reach $304.8 billion by 2025 [126]. - The company is committed to developing innovative therapies for autoimmune diseases through a differentiated approach targeting both B-cell and T-cell signaling pathways [80]. Risks and Challenges - There is a risk of continued losses in the future due to the lengthy and high-investment nature of drug development and commercialization processes [3]. - The company warns that if its in-development drugs fail to complete clinical trials or gain regulatory approval, it may not achieve profitability, impacting its operational capabilities [3]. - The company faces challenges in new drug development, including high R&D costs, long development cycles, and the complexity of clinical trial patient recruitment [136]. - The company must comply with various legal and regulatory requirements in multiple jurisdictions, including the Cayman Islands and China, which may impact its operations and financial status [200]. - The company is exposed to risks from third-party collaborations, including potential delays in clinical trials and disputes over intellectual property, which could hinder development and commercialization efforts [178]. - The rapid technological advancements in the biotech industry pose a risk of obsolescence for the company’s existing and pipeline products if competitors achieve significant breakthroughs [162]. Corporate Governance and Management - The company operates as a red-chip enterprise, listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange's Sci-Tech Innovation Board [6]. - The company has a strong management team with experience from major pharmaceutical companies, enhancing its strategic execution capabilities [31]. - The commercialization team has grown to over 300 members, promoting the product Obutin (宜诺凯®) across hundreds of hospitals nationwide [157]. - The company received the national-level "Specialized and Innovative 'Little Giant' Enterprise" recognition in 2023 [142].

Financial Performance - Total revenue increased by 18.1% from RMB 625.4 million in 2022 to RMB 738.5 million in 2023, primarily driven by the strong sales growth of Oubatinib[3]. - Gross profit rose by 26.6% from RMB 482.0 million in 2022 to RMB 610.1 million in 2023, with a gross margin of 82.6%, up from 77.1% in the previous year[4]. - Net loss decreased by 27.8% from RMB 893.7 million in 2022 to RMB 645.6 million in 2023, reflecting improved operational efficiency[5]. - Total expenses decreased from RMB 1,550.5 million in 2022 to RMB 1,404.3 million in 2023, driven by improved operational efficiency[5]. - Other income and gains rose from RMB 198.2 million in 2022 to RMB 244.2 million in 2023, mainly due to increased bank interest income[5]. - The company reported a total comprehensive loss of RMB 532.09 million for the year ended December 31, 2023, compared to RMB 464.28 million in 2022[169]. Cash and Assets - Cash and bank balances stood at RMB 8,224.6 million as of December 31, 2023, down from RMB 8,697.9 million in 2022[3]. - The net current assets amounted to RMB 6,671.3 million as of December 31, 2023, down from RMB 7,224.3 million[121]. - Trade receivables increased from RMB 127.8 million to RMB 307.6 million, a rise of 140.3%[123]. - As of December 31, 2023, the company's inventory increased to RMB 119.1 million from RMB 65.3 million as of December 31, 2022, indicating a growth of approximately 82.5%[126]. - The company's cash and bank balances decreased from RMB 8,697.9 million to RMB 8,224.6 million, a decline of about 5.4%[138]. Research and Development - Research and development expenses increased to RMB 751.2 million in 2023 from RMB 639.1 million in 2022, indicating ongoing investment in product development[5]. - The company is focused on strategic investments in clinical development and competitive product lines to enhance future growth prospects[5]. - The company aims to establish leadership in the hematological oncology field with a robust pipeline of 13 valuable drugs, including two commercialized products[8]. - The company is advancing multiple candidates in the IND preparation stage and is actively seeking licensing and clinical collaboration opportunities to enhance its pipeline[27]. Clinical Trials and Approvals - The new drug application for relapsed refractory marginal zone lymphoma (MZL) was approved in April 2023, making it the first and only approved BTK inhibitor for this indication in China, with an overall response rate (ORR) of 58.9%[10]. - The company successfully completed patient recruitment for the Phase III registration trial for CLL/SLL first-line treatment in the first half of 2023, with plans to submit the NDA in the second half of 2024[11]. - ICP-248, a new oral BCL-2 inhibitor, is currently in a Phase I dose escalation trial, with preliminary results showing an ORR of 100% in evaluable patients at a 100 mg QD dose[12]. - The company plans to submit a New Drug Application (NDA) for Tafasitamab combined with Lenalidomide in Q2 2024, with expectations for NDA approval in H1 2025[51]. Market and Sales - The sales of Oubatinib increased by 18.5% from RMB 565.9 million in 2022 to RMB 670.7 million in 2023, contributing significantly to revenue growth[3]. - The inclusion of Acalbrutinib in the National Reimbursement Drug List (NRDL) without price reduction is anticipated to further boost sales[10]. - Following the inclusion of its product in the national medical insurance catalog, the company expects strong sales momentum for its drug, Aobutinin (Ibrutinib), in China[23]. - Revenue from mainland China was RMB 673,134 thousand, up 18.5% from RMB 568,035 thousand in 2022[187]. Corporate Governance and Compliance - The audit committee has reviewed the audited consolidated financial statements for the year ended December 31, 2023, ensuring compliance with accounting policies and internal controls[159]. - The company has adopted the standard code of conduct for securities trading as per the listing rules, with no reported violations by employees during the reporting period[154]. - The company plans to continue reviewing its corporate governance structure to ensure compliance with the corporate governance code[153]. Future Outlook - The company aims to establish leadership in the hematological oncology field, focusing on the comprehensive market coverage of multiple myeloma (MM) and non-Hodgkin lymphoma (NHL)[23]. - The company is optimistic about Orelabrutinib's potential as a best-in-class BTK inhibitor for MS and other autoimmune diseases, with ongoing clinical trials showing promising results[76]. - The company plans to expand its product line and enhance commercialization and production capabilities in 2024, marking a transition to a new phase of development[22].

Reportify 产品开启公测以来的几周， 受 到了不少用户的关注，用户中有机构分析师 、 大厂战略部分析师 、VC/PE 投资人、职业股票投资人、资 深老股民还有互联网行业的产品经理、算法工程师等。 大家给予 了我们非常正面的反馈，比如： 「 今天体验下的感觉是挺有想象空间啊[强]。我再体验体验，整体效果已经比同类好多了[强]。 」 「 有引用出处这个设计很好，这一看就是做过苦逼金融实习生的产品经理做出来的产品，没有引用出处会被老板Q到死 」 「 非常不错，尤其对 公司的 slide 和表格数据的处理 」 「 然后一进来，界面清爽清晰，看到有公司 Tab，有对象统计，每一个 Tab 都逻辑清晰； 另一个，我知道 PDF 解析不容易做，RAG也不简单，检查了 一下，引用做的好，且数 字都是准确的，翻译也精准 」 还有很多， 就不一一列举了，当然大家也提了很多很多存在的问题和需求，能快速修改的都处理了，其他还需要时间的功能我们都已经放在 backlog 里了，我们会一个一个去实现。 今天就给大家带来几个重要的更新： - Reportify 功能更新 - 01 . 增加 A 股公司财报和新闻内容 我们之前内容源 ...

Financial Data and Key Metrics Changes - The company raised a total of $1,340 million since its inception, with $2,100 million still available, demonstrating effective and efficient operations [5][12] - Cumulative revenue from 2021 to the third quarter of the previous year reached $310 million [12] Business Line Data and Key Metrics Changes - The company has 13 assets in clinical trials, with 12 from internal efforts, and has two marketed products [9] - The hematology oncology franchise includes two marketed products in liquid cancer and six differentiated assets in the pipeline [10] Market Data and Key Metrics Changes - The company has a comprehensive coverage of indications and mechanisms of action in the liquid tumor space, including multiple myeloma and non-Hodgkin lymphoma [13] - The autoimmune disease portfolio includes six large indications in Phase II and III, with plans to cover more than 15 indications in the next couple of years [11] Company Strategy and Development Direction - The company aims to become a global pharmaceutical leader by developing innovative therapies for oncology and autoimmune diseases, addressing significant unmet medical needs [4] - The strategy includes continuous development of oncology products outside of China and a focus on launching multiple drugs in the next three to four years [40] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of maintaining strict cost-effective operations despite having cash and revenue generation capabilities [12] - The company is optimistic about the upcoming NDA submissions and the progress of ongoing clinical trials, with several milestones expected in 2024 [42] Other Important Information - The company has established a fully integrated drug innovation platform, covering basic research, discovery, clinical development, manufacturing, and commercialization [9] - The company has filed more than 350 patents and established two GMP-compliant manufacturing facilities [9] Q&A Session Summary Question: What are the upcoming milestones for the company? - The company has several NDA submissions planned for 2024, including for arolabronib and tafasitamab, with significant progress in ongoing clinical trials [42]

致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年11月30日 狀態: 新提交 呈交日期: 2023年12月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 09969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | 本月底法定/註冊 ...

公司名稱： 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期： 2023年11月27日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市(註11) | 是 | | | 證券代號 (如於香港聯交所上市) | 09969 | 說明 | | | | | | 發行股份 | (註6及7) | 股份數目 | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | 於下列日期開始時的結存(註2) | 2023年11月14日 | 1,498,662,235 | | | | | | 1). 購回股份(或其他證券)但沒有註銷 | | 32,000 | 0.0021 % | | | % | | 變動日期 | 2023年11月14日 | | | | | | | 2). 購回股份(或其他證券)但沒有註銷 | ...

| 2. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市(註11) | 否 | | | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如於香港聯交所上市) | | 說明 | 該等股份為於上海證券交易所科創板上市的股票 | | | | | 發行股份 | | | 已發行股份佔 有關股份發行前的 | 每股發行價 | 上一個營業日 | 發行價較市值的折讓/ | | (註6及7) | | 股份數目 | 現有已發行股份數目 | (註1及7) | 的每股收市價 | 溢價幅度(百分比) | | | | | 百分比 | | (註5) | (註7) | | | | | (註4、6及7) | | | | FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期： 2023年11月14日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份 ...

Financial Performance - The company achieved a total revenue of RMB 537.36 million for the first nine months of 2023, representing a year-on-year growth of 21.7%[3] - The adjusted net profit for the first nine months of 2023, excluding non-cash items, was a loss of RMB 322 million, while the total net profit was a loss of RMB 539 million, narrowing the loss by RMB 304 million compared to the same period last year[3] - The net profit attributable to shareholders for the third quarter was a loss of RMB 108.96 million, with a basic and diluted earnings per share of -0.06 yuan[5] - The company reported a net loss of ¥4,979,423,376.98 for the first three quarters of 2023, compared to a net loss of ¥4,448,257,868.41 in the same period of 2022[17] - The company's net profit for the first three quarters of 2023 was -539,287,265.88 RMB, compared to -842,652,515.00 RMB in the same period of 2022, showing an improvement of approximately 36%[19] - The company's total comprehensive income for the first three quarters of 2023 was -337,601,250.11 RMB, compared to -279,487,002.07 RMB in 2022[20] - The basic earnings per share for 2023 was -0.31 RMB, an improvement from -0.59 RMB in 2022[20] - The operating profit for the first three quarters of 2023 was -548,854,514.11 RMB, an improvement from -842,055,946.80 RMB in 2022, indicating a recovery trend[19] Cash Flow and Assets - As of September 30, 2023, the company held cash and cash equivalents of approximately RMB 8.58 billion, ensuring sufficient cash flow for ongoing projects[4] - Cash and cash equivalents were reported at ¥8,261,546,048.38, down from ¥8,742,914,140.21 at the end of 2022[16] - The total current assets amounted to ¥8,945,496,793.93, a decrease from ¥9,299,708,518.08 at the end of 2022[16] - The total assets of the company as of the end of the reporting period were RMB 10.04 billion, a decrease of 2.80% compared to the previous year[6] - The total assets as of September 30, 2023, were ¥10,039,622,087.37, compared to ¥10,328,783,979.11 at the end of 2022[17] - The total liabilities as of September 30, 2023, were ¥2,659,650,754.08, slightly down from ¥2,684,457,313.64 at the end of 2022[17] - The company’s cash and cash equivalents at the end of the period increased to 5,440,243,367.28 RMB from 4,414,372,466.48 RMB in the previous year, marking a growth of approximately 23.2%[22] Research and Development - The company's R&D expenditure for the third quarter was RMB 188.52 million, accounting for 117.97% of the revenue, an increase of 17.26 percentage points year-on-year[5] - Research and development expenses increased to 549,716,988.65 RMB in 2023 from 475,344,994.01 RMB in 2022, reflecting a growth of about 15.6%[19] - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[15] Shareholder Information - The number of common shareholders at the end of the reporting period was 20,286[11] - The largest shareholder, HKSCC NOMINEES LIMITED, holds 728,962,157 shares, representing 41.32% of total shares[11] Revenue Sources - The sales growth of the drug Oubatinib (Yinokai®) significantly contributed to the revenue increase since its inclusion in the new medical insurance catalog[3] - Total revenue for the first three quarters of 2023 reached ¥537,361,649.40, an increase of 21.7% compared to ¥441,612,184.36 in the same period of 2022[18] - Total operating costs for the first three quarters of 2023 were ¥1,088,452,691.35, down 16.4% from ¥1,301,756,168.51 in the previous year[18] - The company reported government subsidies of RMB 4.98 million for the third quarter, contributing to its financial performance[7] - The company’s sales revenue from goods and services received cash of 552,799,573.58 RMB in 2023, up from 389,838,923.35 RMB in 2022, representing a growth of about 41.8%[21]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 (1) 2023年第三季度季度報告 此部分公告乃由諾誠健華醫藥有限公司（「本公司」）根據香港聯合交易所有限公司 證券上市規則（「上市規則」）第13.09(2)(a)條及第13.10B條及香港法例第571章證 券及期貨條例第XIVA部的內幕消息條文作出。 茲載列本公司在上海證券交易所網站刊發的《諾誠健華醫藥有限公司2023年第三 季度報告》（「2023年第三季度報告」），僅供參閱。以下為本公司2023年第三季度 報告的譯文，僅供參考。如有任何歧義，概以中文版本為準。 本公司董事（「董事」）會（「董事會」）提醒本公司股東及潛在投資者，本公告所載 資料及財務數據未經審計，已經本公司審核委員會審閱，但未經本公司獨立核數 師審閱。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9969） (1) 2023年第三季度季度報告 及 (2) 關於20 ...